middle.news
BCAL Diagnostics Secures $4.9 Million Funding Boost for Cancer Tests
9:57am on Monday 29th of June, 2026 AEST
•
Healthcare
Read Story
BCAL Diagnostics Secures $4.9 Million Funding Boost for Cancer Tests
9:57am on Monday 29th of June, 2026 AEST
Key Points
Additional $4.9 million funding under $10 million convertible note facility
First $1.4 million tranche of FY2026 R&D tax offset expected end of June
Funds to support development and commercialisation of blood-based cancer tests
Portfolio includes BREASTESTplus, Avantect Pancreatic and Ovarian tests
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bcal Diagnostics (ASX:BDX)
OPEN ARTICLE